TYRA Stock Analysis: Tyra Biosciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.821m USD | 12M Return: 232.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.0M
Qual. Beats: -1
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 4.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tyra Biosciences (NASDAQ: TYRA) is a U.S.-based clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology, primarily in oncology and rare genetic conditions. The company uses its proprietary SNÅP drug design platform to engineer therapies against genetically defined targets, with its most advanced candidate, FGFR3, currently in clinical trials for metastatic urothelial carcinoma and other solid tumors. Its broader pipeline includes TYRA-300 for FGFR3-driven skeletal disorders such as achondroplasia, TYRA-200 for intrahepatic cholangiocarcinoma, and TYRA-430 for hepatocellular carcinoma. As a clinical-stage biotech with no marketed products, the company relies on capital markets and potential partnerships to fund development, and it went public on NASDAQ in September 2021. Tyra was incorporated in 2018 and is headquartered in Carlsbad, California.
- TYRA-300 achondroplasia Phase 2 data readout ahead
- FGFR inhibitor competition from J&J Balversa pressures positioning
- Pipeline cash burn may force dilutive equity offering
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA -3.40 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.25 > 3% & CFO -102.3m > Net Income -131.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 20.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.7m) vs 12m ago 4.06% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.14%; Δ -0.14% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.91 (Total Current Assets 394.6m - Total Current Liabilities 19.3m) / Total Assets 412.0m |
| B: -1.00 (Retained Earnings -410.6m / Total Assets 412.0m) |
| C: -0.35 (EBIT TTM -131.1m / Avg Total Assets 377.8m) |
| D: 15.84 (Book Value of Equity 387.6m / Total Liabilities 24.5m) |
| Altman-Z'' = 17.03 = AAA |
As of July 08, 2026, the stock is trading at USD 31.94 with a total of 754,577 shares traded. Over the past week, the price has changed by -0.53%, over one month by +19.40%, over three months by -15.35% and over the past year by +232.36%.
Current recommended Stop Loss: 29.50 (which is 7.6% or 1.3 ATR below the current price).
Tyra Biosciences has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy TYRA.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 52 | 62.7% |
P/B = 4.5128
Revenue TTM = 0.0 USD
EBIT TTM = -131.1m USD
EBITDA TTM = -130.6m USD
Long Term Debt = 5.21m USD (estimated: total debt 5.70m - short term 488k)
Short Term Debt = 488k USD (from shortTermDebt, last quarter)
Debt = 5.70m USD (from shortLongTermDebtTotal, last quarter) (leases 5.70m already included)
Net Debt = -377.8m USD (calculated: Debt 5.70m - CCE 383.5m)
Enterprise Value = 1.44b USD (1.82b + Debt 5.70m - CCE 383.5m)
Interest Coverage Ratio = unknown (Ebit TTM -131.1m / Interest Expense TTM 0.0)
EV/FCF = -14.08x (Enterprise Value 1.44b / FCF TTM -102.5m)
FCF Yield = -7.10% (FCF TTM -102.5m / Enterprise Value 1.44b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 546k) / Revenue TTM)
Tobins Q-Ratio = 3.50 (Enterprise Value 1.44b / Total Assets 412.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.70m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -103.6m (EBIT -131.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 20.49 (Total Current Assets 394.6m / Total Current Liabilities 19.3m)
Debt / Equity = 0.01 (Debt 5.70m / totalStockholderEquity, last quarter 387.6m)
Debt / EBITDA = 2.89 (negative EBITDA) (Net Debt -377.8m / EBITDA -130.6m)
Debt / FCF = 3.69 (negative FCF - burning cash) (Net Debt -377.8m / FCF TTM -102.5m)
Total Stockholder Equity = 307.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.71% (Net Income -131.1m / Total Assets 412.0m)
RoE = -42.66% (Net Income TTM -131.1m / Total Stockholder Equity 307.4m)
RoCE = -41.95% (EBIT -131.1m / Capital Employed (Equity 307.4m + L.T.Debt 5.21m))
RoIC = -26.34% (negative operating profit) (NOPAT -103.6m / Invested Capital 393.3m)
WACC = 10.63% (E(1.82b)/V(1.83b) * Re(10.66%) + D(5.70m)/V(1.83b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 17.49%
[DCF] Fair Price = unknown (Cash Flow -102.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.14 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.64 | Chg30d=-0.75% | Revisions=-58% | Analysts=15
EPS next Quarter (2026-09-30): EPS=-0.65 | Chg30d=-0.06% | Revisions=-42% | Analysts=15
EPS current Year (2026-12-31): EPS=-2.55 | Chg30d=+0.58% | Revisions=-55% | GrowthEPS=-26.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.82 | Chg30d=+0.64% | Revisions=-58% | GrowthEPS=-10.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -66% (up=5, down=30)